HC Wainwright Reiterates Buy Rating for Septerna (NASDAQ:SEPN)

Septerna (NASDAQ:SEPN)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $40.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 19.44% from the stock’s previous close.

SEPN has been the subject of a number of other research reports. Raymond James Financial boosted their price target on Septerna from $47.00 to $53.00 and gave the company a “strong-buy” rating in a report on Monday, June 8th. Stifel Nicolaus assumed coverage on Septerna in a research report on Friday, May 1st. They set a “buy” rating and a $43.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $60.00 target price on shares of Septerna in a report on Tuesday, March 10th. Truist Financial increased their price target on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. lifted their price objective on Septerna from $34.00 to $38.00 and gave the company an “overweight” rating in a report on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $46.67.

Septerna Trading Down 3.6%

NASDAQ SEPN opened at $33.49 on Wednesday. The stock has a market cap of $1.51 billion, a PE ratio of -41.35 and a beta of 2.39. Septerna has a 12 month low of $10.30 and a 12 month high of $37.99. The company’s 50-day moving average price is $29.58 and its 200-day moving average price is $27.49.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. The company had revenue of $26.52 million during the quarter, compared to analyst estimates of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. As a group, sell-side analysts forecast that Septerna will post -1.57 earnings per share for the current year.

Insider Activity

In related news, COO Elizabeth Bhatt sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $24.34, for a total transaction of $97,360.00. Following the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at $4,240,247.06. This trade represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Daniel D. Long sold 15,000 shares of Septerna stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $35.51, for a total value of $532,650.00. Following the completion of the transaction, the senior vice president owned 96,412 shares in the company, valued at $3,423,590.12. This trade represents a 13.46% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 45,161 shares of company stock worth $1,452,229. 5.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC bought a new position in shares of Septerna during the 1st quarter worth approximately $21,334,000. First Light Asset Management LLC grew its holdings in Septerna by 18.0% in the first quarter. First Light Asset Management LLC now owns 732,860 shares of the company’s stock worth $17,611,000 after purchasing an additional 112,049 shares during the last quarter. Renaissance Technologies LLC purchased a new position in Septerna in the first quarter worth $906,000. Swiss National Bank acquired a new position in shares of Septerna during the first quarter worth $531,000. Finally, Bank of New York Mellon Corp increased its position in shares of Septerna by 6.1% during the first quarter. Bank of New York Mellon Corp now owns 58,709 shares of the company’s stock worth $1,411,000 after purchasing an additional 3,377 shares in the last quarter.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.